MSFT 417.14 0.9731% AAPL 229.0 -0.3438% NVDA 119.37 1.5137% GOOGL 163.38 0.989% GOOG 165.11 1.0465% AMZN 178.5 3.7067% META 521.31 0.5963% AVGO 162.82 3.7533% TSLA 214.11 3.7958% TSM 171.7 1.5075% LLY 960.02 2.1081% V 276.37 0.7473% JPM 224.8 1.1656% UNH 590.2 -0.2316% NVO 139.16 1.1926% WMT 77.23 1.0599% LVMUY 149.005 -0.3844% XOM 117.94 -0.1608% LVMHF 745.0 -0.4011% MA 483.34 0.5283%
Last update at 2024-08-30T20:00:00Z
Q2 2024 Revolution Medicines Inc Earnings Call
Thu 08 Aug 24, 02:28 PMCollegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Thu 01 Aug 24, 02:01 PMRevolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Wed 10 Jul 24, 09:58 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -249.12500M | -187.09100M | -108.53000M | -52.03700M | -41.78900M |
| Minority interest | - | - | - | - | - |
| Net income | -248.70500M | -179.77100M | -108.15900M | -47.66400M | -41.78900M |
| Selling general administrative | 40.59M | 30.45M | 21.43M | 12.41M | 9.41M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 35.38M | 29.39M | 42.98M | 50.04M | 20.16M |
| Reconciled depreciation | 9.66M | 7.33M | 6.54M | 3.34M | 1.76M |
| Ebit | -258.27900M | -188.00800M | -110.69700M | -54.12000M | -41.67300M |
| Ebitda | -249.12500M | -187.07900M | -108.45900M | -48.58900M | -39.90900M |
| Depreciation and amortization | 9.15M | 0.93M | 2.24M | 5.53M | 1.76M |
| Non operating income net other | - | 0.93M | 2.24M | - | - |
| Operating income | -258.27900M | -188.00800M | -110.69700M | -54.12000M | -40.32900M |
| Other operating expenses | 293.66M | 217.40M | 153.68M | 104.16M | 60.49M |
| Interest expense | -9.65600M | 0.01M | 0.07M | 0.11M | 0.12M |
| Tax provision | -0.42000M | 0.00000M | -0.37100M | -4.37300M | - |
| Interest income | 9.15M | 0.93M | 2.24M | 2.19M | 0.78M |
| Net interest income | 9.15M | 0.92M | 2.17M | 2.08M | 0.66M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.42000M | -7.32000M | -0.37100M | -4.37300M | -1.34400M |
| Total revenue | 35.38M | 29.39M | 42.98M | 50.04M | 20.16M |
| Total operating expenses | 293.66M | 217.40M | 153.68M | 104.16M | 60.49M |
| Cost of revenue | - | - | - | - | 50.28M |
| Total other income expense net | 9.15M | 0.92M | 2.17M | 2.08M | -2.12100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -248.70500M | -187.09100M | -108.15900M | -47.66400M | -41.78900M |
| Net income applicable to common shares | -248.70500M | -187.09100M | -110.37800M | -61.90200M | -48.82000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2088.59M | 811.93M | 737.99M | 567.40M | 220.53M |
| Intangible assets | 57.74M | 58.81M | 59.88M | 60.95M | 62.01M |
| Earning assets | - | - | - | - | - |
| Other current assets | 25.07M | 10.57M | 6.79M | 6.99M | 2.49M |
| Total liab | 262.40M | 126.74M | 135.42M | 92.72M | 67.99M |
| Total stockholder equity | 1826.19M | 685.19M | 602.57M | 474.68M | 152.53M |
| Deferred long term liab | - | 0.60M | 0.50M | 7.44M | 2.10M |
| Other current liab | 74.69M | 29.45M | -20.27100M | 10.30M | 14.36M |
| Common stock | 0.02M | 0.00900M | 0.00800M | 0.00700M | - |
| Capital stock | 0.02M | 0.00900M | 0.00800M | 0.00700M | 305.11M |
| Retained earnings | -1137.70800M | -701.34100M | -452.63600M | -265.54500M | -157.38600M |
| Other liab | - | 7.33M | 14.65M | 16.56M | 24.94M |
| Good will | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M |
| Other assets | 0.00000M | 4.59M | 2.50M | 1.39M | 2.78M |
| Cash | 696.15M | 161.41M | 108.50M | 104.27M | 16.66M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 143.85M | 61.98M | 18.93M | 47.18M | 43.05M |
| Current deferred revenue | - | 4.46M | 18.93M | 20.59M | 17.12M |
| Net debt | -608.20400M | -97.20700M | -41.86400M | -71.60400M | -16.48700M |
| Short term debt | 7.37M | 6.77M | 6.21M | 3.67M | 0.17M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 87.94M | 64.20M | 66.63M | 32.66M | 0.17M |
| Other stockholder equity | 2963.34M | 1388.30M | 317.58M | 172.70M | 4.74M |
| Property plant equipment | - | 73.74M | 71.24M | 8.90M | 7.15M |
| Total current assets | 1879.28M | 660.18M | 577.05M | 454.12M | 133.98M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 611.77M | 528.08M | 399.12M | -229.19500M |
| Short term investments | 1156.81M | 483.53M | 468.56M | 336.47M | 106.10M |
| Net receivables | 1.25M | 4.67M | 5.93M | 6.39M | 8.74M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.00000M | - | -12.71900M | - | - |
| Accounts payable | 61.79M | 21.31M | 14.06M | 12.61M | 11.40M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.54M | -1.78000M | -0.37600M | 0.12M | 0.07M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.00800M | 0.00700M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -452.63600M | -265.54500M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 7.03M | 4.59M | 15.21M | 1.39M | 2.78M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 209.31M | 151.75M | 160.93M | 113.28M | 86.55M |
| Capital lease obligations | 87.94M | 64.20M | 66.63M | 32.66M | 0.17M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -24.11600M | -135.58900M | -231.30000M | -105.57600M | -1.33900M |
| Change to liabilities | -7.60300M | 0.58M | -5.92300M | -12.50100M | 44.61M |
| Total cashflows from investing activities | -24.11600M | -142.11700M | -234.23300M | -101.96900M | -1.33900M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 301.43M | 294.18M | 422.78M | 98.66M | 60.85M |
| Change to operating activities | -7.14200M | 7.68M | 0.68M | 5.11M | 0.76M |
| Net income | -248.70500M | -187.09100M | -108.15900M | -47.66400M | -41.78900M |
| Change in cash | 52.91M | 4.88M | 88.48M | -52.92700M | 60.72M |
| Begin period cash flow | 110.23M | 105.35M | 16.87M | 69.80M | 9.08M |
| End period cash flow | 163.15M | 110.23M | 105.35M | 16.87M | 69.80M |
| Total cash from operating activities | -224.40100M | -147.18000M | -100.06400M | -49.61600M | 1.21M |
| Issuance of capital stock | 298.05M | 291.24M | 420.07M | 100.03M | 60.56M |
| Depreciation | 9.66M | 7.33M | 6.54M | 3.34M | 1.76M |
| Other cashflows from investing activities | - | - | - | -99.38000M | 0.16M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 7.68M | - | - | - |
| Change to account receivables | 1.26M | 0.46M | 2.34M | -1.43400M | -7.30300M |
| Sale purchase of stock | 1.86M | 1.88M | 0.83M | 100.26M | 60.85M |
| Other cashflows from financing activities | 1.52M | 1.06M | 1.88M | -1.37000M | 60.43M |
| Change to netincome | 28.14M | 23.86M | 8.51M | 3.53M | 3.18M |
| Capital expenditures | 10.82M | 6.53M | 2.93M | 2.59M | 1.50M |
| Change receivables | - | 0.46M | 2.34M | - | - |
| Cash flows other operating | - | 0.17M | -1.48400M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 4.88M | 88.48M | - | - |
| Change in working capital | -13.48900M | 8.72M | -8.30400M | -8.82800M | 38.06M |
| Stock based compensation | 31.20M | 20.72M | 8.89M | 3.16M | 0.85M |
| Other non cash items | -2.64000M | 3.13M | 1.34M | 4.75M | 2.12M |
| Free cash flow | -235.21700M | -153.70800M | -102.99700M | -52.20500M | -0.28600M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines Inc |
0.83 1.99% | 42.63 | - | - | 512.99 | 3.25 | 360.71 | -9.7077 |
| NVO Novo Nordisk A/S |
1.64 1.19% | 139.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.0025 0.0018% | 138.74 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
2.54 0.51% | 495.89 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
5.76 0.49% | 1184.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
700 Saginaw Drive, Redwood City, CA, United States, 94063
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark A. Goldsmith Ph.D. | CEO, Pres & Chairman | 1962 |
| Mr. Jack Anders | Chief Financial Officer | 1977 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 1963 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Pres of R&D | 1961 |
| Ms. Xiaolin Wang | Exec. VP of Clinical Devel. | 1971 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | NA |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 1981 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | NA |
| Mr. David L. Pompliano Ph.D. | Founding Chief Scientific Officer | NA |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...